Describes the creation and operation of the first of two heavyweight teams to develop new drugs and running. The focus is on one of the teams, Evista, although the comparison with the other team, Zyprexa, are included. Lilly need to decide on the next step (postlaunch) to control the scroll to Evista. "Hide
by Stephen S. Kolesnik, Matthew C. Verlinden Source: Harvard Business School 24 pages. Publication Date: Mar 09, 1999. Prod. #: 699016-PDF-ENG
Related Case Solutions & Analyses:
We Gave Them a Tool but Hardly Anyones Using It Untangling the Knowledge Management Dilemma at TPA
Disney Crisis Exercise
Matrix Capital Management (A)
Identifying Firm Capital Structure
Note: Credit Rating Agencies
Tong Lung Metal Industry Co. Ltd.
Shui On: Branding Properties for Sustainable Growth in China
USInteractive
HEWLETT-PACKARD & A COMMON SUPPLIER CODE OF CONDUCT
Travel Centers of America
